Table 2.
Univariate analysis for the association between clinical characteristics and survival in all and landmark groups with metastatic colon cancer received mFOLFOX6 as first-line treatment
| All patients | Landmark patients | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PFS | OS | PFS | OS | |||||||
| N (%) | Survival (months) Median (95%CI) |
P value | Survival (months) Median (95%CI) |
P value | N (%) | Survival (months) Median (95%CI) |
P value | Survival (months) Median (95%CI) |
P value | |
| KPS | ||||||||||
| 90 | 273 (94) | 5.9 (5.1–6.9) | 0.287 | 17.5 (8.1–22.8) | 0.371 | 218 (94) | 6.3 (5.6–6.9) | 0.154 | 17.8 (17.1–23.9) | 0.071 |
| 70–80 | 17 (6) | 2.7 (2.6–2.9) | 15.4 (9.8–18.9) | 14 (6) | 2.8 (2.6–3.7) | 15.6 (10.9–20.9) | ||||
| Pathological differentiation | ||||||||||
| Well-moderate | 229 (79) | 5.7 (4.6–6.8) | 0.053 | 12.6 (11.6–13.7) | 0.060 | 187 (80) | 6.3 (5.2–7.4) | 0.785 | 13.7 (10.9–16.6) | 0.040 |
| poor | 61 (21) | 5.3 (2.7–7.9) | 10.2 (5.9–14.7) | 45 (20) | 6.2 (4.8–7.7) | 12.0 (8.1–15.9) | ||||
| Liver metastasis | ||||||||||
| presence | 222 (76) | 4.9 (4.0–5.9) | 0.116 | 12.1 (10.7–13.6) | 0.282 | 178 (77) | 5.9 (4.9–6.9) | 0.195 | 12.0 (8.1–15.9) | 0.132 |
| absence | 68 (24) | 6.9 (6.3–7.5) | 16.3 (10.5–21.4) | 54 (23) | 6.2 (4.8–7.7) | 12.8 (11.4–14.1) | ||||
| Severity of CIN | ||||||||||
| Mild | 132 (46) | 6.9 (5.9–7.8) | <0.001 | 16.3 (13.4–19.2) | <0.001 | 120 (52) | 6.9 (6.1–7.9) | <0.001 | 18.1 (13.6–22.4) | <0.001 |
| Severe | 49 (17) | 7.2 (5.7–8.7) | 16.1 (7.3–25.1) | 42 (18) | 7.6 (6.0–7.9) | 18.8 (11.0–26.7) | ||||
| Absence | 109 (37) | 3.2 (2.6–3.8) | 6.7 (5.4–7.9) | 70 (30) | 3.4 (2.7–4.1) | 9.5 (8.0–10.9) | ||||
| M vs. A | <0.001 | <0.001 | <0.001 | <0.001 | ||||||
| L vs. A | <0.001 | <0.001 | <0.001 | <0.001 | ||||||
| M vs. L | 0.416 | 0.139 | 0.360 | 0.127 | ||||||
| Timing of CIN | ||||||||||
| Early-onset | 141 (49) | 7.2 (6.4–8.0) | <0.001 | 20.7 (16.1–25.4) | <0.001 | 130 (56) | 7.7 (6.5–8.9) | <0.001 | 21.9 (18.5–25.7) | <0.001 |
| Late-onset | 40 (14) | 6.2 (5.9–6.6) | 12.8 (11.6–13.9) | 32 (14) | 6.3 (5.9–6.6) | 13.3 (11.9–14.7) | ||||
| Absence | 109 (37) | 3.2 (2.7–3.8) | 6.7 (5.6–7.8) | 70 (30) | 3.4 (2.7–4.1) | 9.5 (7.9–10.9) | ||||
| E vs. A | <0.001 | <0.001 | <0.001 | <0.001 | ||||||
| L vs. A | <0.001 | <0.001 | 0.003 | 0.009 | ||||||
| E vs. L | 0.115 | <0.001 | 0.095 | <0.001 | ||||||
Abbreviation CIN chemotherapy-induced neutropenia, M mild CIN, S severe CIN, A absence of CIN, E early-onset CIN, L late-onset CIN
A two-sided significance level of 0.05 was used to evaluate statistical significance